NCT00405717

Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel

Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,300 (estimated)
• Sponsor: Shenyang Northern Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Clopidogrel and statins are frequently coadministered in patients with ischemic heart diseases. Recent reports suggested that clopidogrel's effectiveness in inhibiting adenosine diphosphate (ADP)-induced platelets aggregation is attenuated by co-administration of certain statins. The objective of the present study is to define which kind of statins might interfere with the antiaggregation property of clopidogrel in patients with acute coronary Syndrome after percutaneous coronary intervention (PCI). In this prospective randomized study, all patients in test group will receive clopidogrel plus atorvastatin, and all patients in control group will receive clopidogrel plus pravastatin. All patients will be followed up for one year. The primary endpoints include death, non fatal AMI, urgent revascularization. The secondary endpoints include hemorrhage events and subacute thrombosis events at 1 year.

Conditions

• Ischemic Heart Disease
• Acute Coronary Syndromes

Interventions

Type	Name	Description
DRUG	atorvastatin,pravastatin

Timeline

• Start date: 2006-02-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2006-11-30
• Last updated: 2008-11-07

Locations

1 site across 1 country: China